PARRC: what clinicians are saying
pembrolizumab in high-grade T1 bladder cancer · NCT06770582 ↗ · Phase 2 · National Cancer Institute (NCI)
A radiation oncologist whose trial involvement is unconfirmed encouraged participation in PARRC; a urologist responded favorably to its launch. Neither comment expressed a treatment preference. The broader treatment context tentatively raised chemoradiation alongside a reported audience preference for cystectomy, relaying a presentation by a speaker described as a trial principal investigator. An enrollment suggestion in BCG-unresponsive CIS left eligibility unclear. The comments do not assess comparative benefit, safety or quality-of-life trade-offs.
Created with AI · how we check it
- edition 1
- commentary checked Nov 21, 2026
- 7 verified statements
This edition $750, with MCP access for your AI agent. Get this report
3 findings, and what sits behind each
01. PARRC: a clinician encourages opening and accrual; one welcomes activation
2 of the report's 3 cited clinicians · 2 statements from 2 speakers in 2 sources · 3 passages
Limitations recorded: 3.
Draws on: Design and conduct.
02. BCG-unresponsive NMIBC: a clinician relays a question on chemoradiation vs cystectomy
1 of the report's 3 cited clinicians · 2 statements from 1 speaker in 2 sources · 2 passages
Limitations recorded: 4.
Draws on: Population and setting, Design and conduct.
Beyond the trial population
03. BCG-unresponsive CIS: a clinician proposes enrollment in NRG GU014
1 of the report's 3 cited clinicians · 2 statements from 1 speaker in 3 sources · 4 passages
Limitations recorded: 1.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 3
2 of the report's 3 cited clinicians
PARRC: a clinician encourages opening and accrual; one welcomes activation
2 statements from 2 speakers in 2 sources
1 of the 2 named speakers in this finding holds this view, a confirmed clinician; 1 of the 2 holds its caveat, “one welcomes activation”
- 2
- statements
- 3
- passages
- 2
- sources
- 2
- speakers
What the statements areViews 2Questions and uncertainty 0Clinical experience 0Comparisons 0Restated results and context 0Statement-to-passage links (a passage can back several statements)Supporting a statement 2Giving context 1Recorded with the findingLimitations: 3
2 posts and articles
Draws on: Design and conduct.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
1 of the 3 findings and 2 of the 7 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (3)
HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians.
The full PARRC report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
In PARRC’s setting of BCG-unresponsive high-grade T1 bladder cancer, could chemoradiation be considered instead of cystectomy?
From finding F1 (2 statements from 1 speaker in 2 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 26commentary sources screened
- 6sources cited by verified statements
- 4named in screened sources
- 3speakers cited in the report
- 3cited speakers with a verified identity
3 cited clinicians, speakers with a confirmed clinical role, of them 3 physicians. By role and specialty:
- 2 physician, Radiation oncology
- 1 physician, Urology
Also in the sources: 2 organizational or shared accounts, not counted as people.
- 7verified statements, each linked to its source
- 4of them from speakers with a confirmed clinical role
- 3findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 3 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified statements with short source quotes and links | 7 | Paid |
| Who said each statement: the cited speakers | 3 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 3 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 3 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 9 | Free |
| Sources with links | 6 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
4 discussed · 5 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Bladder intact event-free survival (BIEFS)no commentary found | 0 | 0 |
| Primary endpoint: Global quality of lifeno commentary found | 0 | 0 |
| Secondary endpointsno commentary found | 0 | 0 |
| Population and setting | 2 | 2 |
| The comparisonThe registered arms and what clinicians said about how they compare.no commentary found | 0 | 0 |
| Safety and tolerabilityno commentary found | 0 | 0 |
| Design and conduct | 3 | 3 |
| Cystectomy versus consideration of chemoradiation | 2 | 2 |
| Enrollment suggestion within a BCG-unresponsive CIS exchange | 1 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
7 verified statements from 6 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 0 statements · 0% | ||||
| YouTube | 0 | 0 | 1 | |
| Posts · 7 statements · 100% | ||||
| X threads | 7 | 6 | 19 | |
| Bluesky threads | 0 | 0 | 6 | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 7 / quarter
- Screened window
- Jan 17, 2025 → Nov 19, 2026
- Cited window
- Feb 14, 2025 → Aug 28, 2026
- Retrieved
- Nov 21, 2026
The trial
from ClinicalTrials.gov- Title
- Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC Trial)
- Registry
- NCT06770582
- Study IDs
- NCI-2025-00008 · NRG-GU014 (NRG Oncology; CTEP) · U10CA180868
- Sponsor
- National Cancer Institute (NCI)
- Design
- Phase 2 · Interventional, randomized, parallel
- Status
- Recruiting
- Enrollment
- 160 estimated
- Registered
- 2025-01-13
- Start
- 2025-06-03 actual
- Primary completion
- 2032-02-01 estimated
- Primary endpoints
- Bladder intact event-free survival (BIEFS)
- Global quality of life
- Interventions
- 10 registered
More on: Urothelial carcinoma, pembrolizumab
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on economic and patient-goal trade-offs in sequencing bladder-sparing treatments versus cystectomy.
- 21 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 35 sources about other trials or topics are not included; discussion that uses 2 names the trial shares with other things, without the trial's condition or setting, may be missing.
- Brief social-media statements provide little explanation of patient selection, treatment trade-offs or practical implementation; their strength should not be expanded into prescribing recommendations.
Show all 10 known gaps +Fewer −
- A reported audience preference and organizational repetition do not establish independent clinician consensus.
- Discussion that did not name the trial or used different wording may be absent, so the report is not representative of all public or HCP discussion.
- No full protocol or exact-trial results publication accompanies these views in the sources reviewed for this edition; the posts do not support a comprehensive appraisal of methods or outcomes.
- The linked-article quotation about unmet need is incomplete and does not identify its speaker, so it cannot be assigned to a named clinician.
- The enrollment suggestion made in the CIS exchange does not establish which patients would satisfy PARRC eligibility.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 21, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. PARRC (NCT06770582): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 21, 2026. https://www.erudio.com/reports/parrc-nct06770582
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "PARRC" (NCT06770582), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "parrc-nct06770582". If you cannot make requests, read https://www.erudio.com/reports/parrc-nct06770582.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT06770582", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT06770582 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/parrc-nct06770582.json
curl https://www.erudio.com/reports/parrc-nct06770582.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "parrc-nct06770582" })release 280dbd99fce2a08f66a8e44495127293d894aa6465b86f49fc4553abba353082
Questions
How much does the PARRC report cost?
One edition costs $750 (Focused · 7 verified statements · 4 from 3 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the PARRC report cover?
7 statements from 6 sources (6 posts), 4 of them from 3 confirmed clinicians, each linked to its source. Commentary checked Nov 21, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the PARRC report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "parrc-nct06770582" }) previews it and create_order({ "report": "parrc-nct06770582", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the PARRC report?
Edition 1 (version 1.0.0), accepted Nov 21, 2026 UTC; last checked for new commentary Nov 21, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.